TITLE

Ruxolitinib for Myelofibrosis

PUB. DATE
May 2012
SOURCE
New England Journal of Medicine;5/24/2012, Vol. 366 Issue 21, p2031
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
75987871

 

Related Articles

  • FDA approves drug for myelofibrosis. Coleman, Craig I. // Drug Topics;Mar2012, Vol. 156 Issue 3, p57 

    The article reports that the U.S. Food & Drug Administration (FDA) has approved the drug ruxolitinib for the treatment of myelofibrosis, a rare bone marrow disease. Ruxolitinib's efficacy was established in 2 randomized trials in patients with primary myelofibrosis, post-polycythemia vera...

  • Safety and efficacy of ruxolitinib in a profoundly thrombocytopenic patient with myelofibrosis. Armstrong, C.; Maung, S.; Neary, P.; McHugh, J.; Enright, H. // Annals of Hematology;Apr2015, Vol. 94 Issue 4, p711 

    A letter to the editor on the article "Safety and efficacy of ruxolitinib in a profoundly thrombocytopenic patient with myelofibrosis" by C. Armstrong and others is presented.

  • Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis. Barosi, G; Gale, R P // Leukemia (08876924);Mar2015, Vol. 29 Issue 3, p740 

    A response from the author of the article "ruxolitinib and survival improvement in patients with myelofibrosis," in the previous issue is presented.

  • Ruxolitinib.  // Reactions Weekly;Aug2015, Vol. 1566 Issue 1, p204 

    An abstract of the article "Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis," by H. Gisslinger and colleagues is presented.

  • Ruxolitinib.  // Reactions Weekly;Aug2015, Vol. 1562 Issue 1, p183 

    The article describes cases of various toxicities, such as hyperkalaemia, fatigue and dizzines, that developed in 8 patients with myelofibrosis during administration of ruxolitinib.

  • Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve? Molica, Matteo; Serrao, Alessandra; Saracino, Roberta; Zacheo, Irene; Stingone, Christof; Alimena, Giuliana; Breccia, Massimo // Annals of Hematology;Nov2014, Vol. 93 Issue 11, p1951 

    A letter to the editor is presented which discusses the disappearance of fibrosis following treatment with ruxolitinib in patients with secondary myelofibrosis.

  • Ruxolitinib for myelofibrosis therapy: current context, pros and cons. Pardanani, A // Leukemia (08876924);Jul2012, Vol. 26 Issue 7, p1449 

    The author discusses the pros and cons of ruxolitinib for the treatment of myelofibrosis. The author mentions a clinical trial which supports that ruxolitinib could be the best available therapy for the management of the said disease. The author states that short-term and long-term...

  • Ruxolitinib. Mesa, Ruben A.; Yasothan, Uma; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Feb2012, Vol. 11 Issue 2, p103 

    In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera...

  • Favorable Data for Ruxolitinib and for a New JAK Inhibitor in Myelofibrosis. Canavan, Neil // American Health & Drug Benefits;Feb Special Issue 2012, Vol. 5, p23 

    The article reports on research which was conducted on the drug ruxolitinib and found that it provides a survival advantage for patients with myelofibrosis and discusses research which is being conducted in 2012 on the drug CYT387, which will be used to treat myelofibrosis.

  • Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib. Iurlo, Alessandra; Cattaneo, Daniele; Boiocchi, Leonardo; Orofino, Nicola; Fermo, Elisa; Cortelezzi, Agostino; Gianelli, Umberto // Annals of Hematology;Oct2015, Vol. 94 Issue 10, p1749 

    The article discusses clinical and morphologic features in five post-polycythemic myelofibrosis patients who were treated with ruxolitinib. It compares cellularity, hematopoietic lineages and stromal modifications in bone marrow biopsies of myelofibrosis patients. It further mentions variability...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics